Oppenheimer initiated coverage on Corvus Pharmaceuticals with a new price target
$CRVS
Biotechnology: Pharmaceutical Preparations
Health Care
Oppenheimer initiated coverage of Corvus Pharmaceuticals with a rating of Outperform and set a new price target of $7.00